PT2041308E - Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3 - Google Patents

Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3 Download PDF

Info

Publication number
PT2041308E
PT2041308E PT07786793T PT07786793T PT2041308E PT 2041308 E PT2041308 E PT 2041308E PT 07786793 T PT07786793 T PT 07786793T PT 07786793 T PT07786793 T PT 07786793T PT 2041308 E PT2041308 E PT 2041308E
Authority
PT
Portugal
Prior art keywords
mage
seq
probe
primer
pcr
Prior art date
Application number
PT07786793T
Other languages
English (en)
Portuguese (pt)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne-Marie Beer
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PT2041308E publication Critical patent/PT2041308E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT07786793T 2006-06-21 2007-06-21 Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3 PT2041308E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method

Publications (1)

Publication Number Publication Date
PT2041308E true PT2041308E (pt) 2012-10-09

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07786793T PT2041308E (pt) 2006-06-21 2007-06-21 Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3

Country Status (27)

Country Link
US (1) US8936919B2 (enExample)
EP (1) EP2041308B1 (enExample)
JP (2) JP2009540812A (enExample)
KR (1) KR101455589B1 (enExample)
CN (1) CN101506383B (enExample)
AU (1) AU2007263019B2 (enExample)
BR (1) BRPI0713599A2 (enExample)
CA (1) CA2656909A1 (enExample)
CO (1) CO6140072A2 (enExample)
CY (1) CY1113290T1 (enExample)
DK (1) DK2041308T3 (enExample)
EA (1) EA016347B1 (enExample)
ES (1) ES2389513T3 (enExample)
GB (1) GB0612342D0 (enExample)
HR (1) HRP20120761T1 (enExample)
IL (1) IL195975A (enExample)
MA (1) MA30565B1 (enExample)
MX (1) MX2008016493A (enExample)
MY (1) MY147511A (enExample)
NO (1) NO20085290L (enExample)
NZ (1) NZ573809A (enExample)
PL (1) PL2041308T3 (enExample)
PT (1) PT2041308E (enExample)
SI (1) SI2041308T1 (enExample)
UA (1) UA95956C2 (enExample)
WO (1) WO2007147876A2 (enExample)
ZA (1) ZA200810695B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932723B (zh) 2007-09-17 2014-09-10 肿瘤甲基化科学公司 改进的对mage-a表达的检测
CA2805035A1 (en) * 2010-07-22 2012-01-26 Glaxosmithkline Biologicals S.A. Novel antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
ATE342730T1 (de) * 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
DE69524264T2 (de) * 1994-03-01 2002-07-18 Ludwig Institute For Cancer Research, New York Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
DE69942214D1 (de) * 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
AU5992999A (en) * 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
JP2005515192A (ja) * 2001-11-29 2005-05-26 ダンドリット バイオテック アクティーゼルスカブ ヒト又は動物において免疫応答を誘導するための医薬組成物
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US7910295B2 (en) * 2002-11-14 2011-03-22 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimarker quantitative RT-PCR
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
SI2041308T1 (sl) 2012-10-30
KR20090034900A (ko) 2009-04-08
BRPI0713599A2 (pt) 2012-11-06
GB0612342D0 (en) 2006-08-02
JP2009540812A (ja) 2009-11-26
PL2041308T3 (pl) 2012-11-30
KR101455589B1 (ko) 2014-10-28
EP2041308B1 (en) 2012-07-11
JP2013046630A (ja) 2013-03-07
WO2007147876A2 (en) 2007-12-27
EA200802356A1 (ru) 2009-06-30
MX2008016493A (es) 2009-05-21
AU2007263019A1 (en) 2007-12-27
NZ573809A (en) 2011-12-22
ES2389513T3 (es) 2012-10-26
US8936919B2 (en) 2015-01-20
CY1113290T1 (el) 2016-04-13
UA95956C2 (uk) 2011-09-26
CO6140072A2 (es) 2010-03-19
EA016347B1 (ru) 2012-04-30
CA2656909A1 (en) 2007-12-27
IL195975A0 (en) 2009-09-01
DK2041308T3 (da) 2012-10-08
CN101506383B (zh) 2013-08-28
CN101506383A (zh) 2009-08-12
US20120040341A1 (en) 2012-02-16
HRP20120761T1 (hr) 2012-10-31
WO2007147876A3 (en) 2008-05-15
EP2041308A2 (en) 2009-04-01
HK1127627A1 (en) 2009-10-02
MA30565B1 (fr) 2009-07-01
NO20085290L (no) 2009-01-19
JP5705191B2 (ja) 2015-04-22
ZA200810695B (en) 2014-03-26
AU2007263019B2 (en) 2012-11-08
MY147511A (en) 2012-12-31
IL195975A (en) 2012-08-30

Similar Documents

Publication Publication Date Title
KR101437718B1 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
JP6032616B2 (ja) Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法
JP5009787B2 (ja) Ｅｒｇ遺伝子を単独でまたは前立腺癌中で過剰発現もしくは過少発現される他の遺伝子と組み合わせて用いる、前立腺癌を診断または治療する方法
JP6493681B2 (ja) 肺がんで見出された新規融合遺伝子
RU2491289C2 (ru) Полинуклеотидные праймеры
Fischer et al. Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA
CA2877864C (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
JP5769952B2 (ja) Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
KR20030081339A (ko) Ｅｒｃｃ１ 및 ｔｓ 발현을 기초로 한 화학요법 섭생을결정하는 방법
EP2686450A1 (en) Biomarkers for predicting the recurrence of colorectal cancer metastasis
Venesio et al. Oxidative DNA damage drives carcinogenesis in MUTYH-associated-polyposis by specific mutations of mitochondrial and MAPK genes
Miyamae et al. Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue
PT2041308E (pt) Método para a detecção e diagnóstico do cancro envolvendo iniciadores e sondas para a detecção específica do marcador mage�a3
Symvoulakis et al. Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer
KR102600344B1 (ko) Kras 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트
JP2004535806A (ja) 癌
WO2013177705A1 (en) Genotyping assay for identifying chromosomal rearrangements
Sánchez-Pernaute et al. Overexpression of c-myc and loss of heterozigosity on 2p, 3p, 5q, 17p and 18q in sporadic colorectal carcinoma
WO2016116935A1 (en) Use of rasa2 as a prognostic and therapeutic marker for melanoma
KR102600347B1 (ko) Nras 유전자 돌연변이 검출용 조성물 및 이를 포함하는 키트
US20240415839A1 (en) Identification and Treatment of Cancers Associated with RASGRF1 Gene Fusions
HK1127627B (en) Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker
KR101766005B1 (ko) 폐암 환자의 생존기간 예측용 키트와 생존기간 예측을 위한 정보 제공 방법
KR101805977B1 (ko) 폐암 환자의 생존기간 예측용 키트와 생존기간 예측을 위한 정보 제공 방법
Caruso 11 Role of mismatch repair proteins and microsatellite instability in colon carcinoma